These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19733016)

  • 1. Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial.
    Suwinski R; Jaworska M; Nikiel B; Grzegorz W; Bankowska-Wozniak M; Wojciech M; Krzysztof S; Dariusz L
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):438-46. PubMed ID: 19733016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
    Buffa FM; Bentzen SM; Daley FM; Dische S; Saunders MI; Richman PI; Wilson GD
    Clin Cancer Res; 2004 Jun; 10(11):3745-54. PubMed ID: 15173081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer.
    Suwiński R; Bańkowska-Woźniak M; Majewski W; Idasiak A; Maciejewski A; Ziółkowska E; Windorbska W; Składowski K; Miszczyk L; Maciejewski B
    Radiother Oncol; 2008 May; 87(2):155-63. PubMed ID: 18342964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
    Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
    J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.
    Skladowski K; Maciejewski B; Golen M; Tarnawski R; Slosarek K; Suwinski R; Sygula M; Wygoda A
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):706-13. PubMed ID: 17011446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.
    Eriksen JG; Buffa FM; Alsner J; Steiniche T; Bentzen SM; Overgaard J
    Radiother Oncol; 2004 Sep; 72(3):275-82. PubMed ID: 15450725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.
    Smith BD; Smith GL; Carter D; DiGiovanna MP; Kasowitz KM; Sasaki CT; Haffty BG
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):780-5. PubMed ID: 11448349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.
    Eriksen JG; Steiniche T; Overgaard J;
    Acta Oncol; 2005; 44(1):50-8. PubMed ID: 15848906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
    Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.
    Suwinski R; Bankowska-Wozniak M; Majewski W; Sowa A; Idasiak A; Ziolkowska E; Windorbska W; Tarnawski R; Skladowski K; Maciejewski B
    Radiother Oncol; 2005 Oct; 77(1):58-64. PubMed ID: 16157401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy.
    Ahmed WA; Suzuki K; Imaeda Y; Horibe Y
    Auris Nasus Larynx; 2008 Jun; 35(2):213-9. PubMed ID: 17996416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.
    Siddiqui F; Pajak TF; Watkins-Bruner D; Konski AA; Coyne JC; Gwede CK; Garden AS; Spencer SA; Jones C; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):353-60. PubMed ID: 17889449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of epidermal growth factor receptor and cyclin D1 in pretreatment biopsies as a predictive factor of radiotherapy efficacy in early glottic cancer.
    Chang AR; Wu HG; Park CI; Jun YK; Kim CW
    Head Neck; 2008 Jul; 30(7):852-7. PubMed ID: 18302259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy.
    Langendijk JA; Slotman BJ; van der Waal I; Doornaert P; Berkof J; Leemans CR
    Cancer; 2005 Oct; 104(7):1408-17. PubMed ID: 16130134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.
    Psyrri A; Yu Z; Weinberger PM; Sasaki C; Haffty B; Camp R; Rimm D; Burtness BA
    Clin Cancer Res; 2005 Aug; 11(16):5856-62. PubMed ID: 16115926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer.
    Nagy B; Tiszlavicz L; Eller J; Molnar J; Thurzo L
    In Vivo; 2003; 17(1):93-6. PubMed ID: 12655798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.
    Bova RJ; Quinn DI; Nankervis JS; Cole IE; Sheridan BF; Jensen MJ; Morgan GJ; Hughes CJ; Sutherland RL
    Clin Cancer Res; 1999 Oct; 5(10):2810-9. PubMed ID: 10537346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.